Abstract 529P
Background
Ramucirumab (RAM) plus docetaxel (DOC) combination therapy is one of the standard treatment options for second-line in patients with advanced NSCLC. Previous studies reported that history of pre-administration of immune checkpoint inhibitors was related to good outcomes with RAM plus DOC. However, the clinical significance of RAM plus DOC after combined immunotherapy is little known. Therefore, we evaluated RAM plus DOC after combined chemoimmunotherapy and attempted to identify predictors for their outcomes.
Methods
This multicenter prospective study aimed to investigate the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy. The primary endpoint was progression-free survival (PFS). The secondary endpoints are objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of adverse events (AEs). Serum cytokines at the start of treatment were measured as an exploratory investigation.
Results
A total of 44 patients were enrolled, at 10 Japanese institutions from November 2019 and March 2021. The median PFS was 6.3 months (95% confidence interval [CI]: 4.2–8.8), and the median OS was 22.6 months (95% CI: 13.9–NE). The ORR and DCR were 36.4% (95% CI: 22.4–52.2) and 72.7% (95% CI: 57.2–85.0). High VEGF-D groups had significantly shortened PFS and OS. The combination of high VEGF-A and low VEGF-D had a longer PFS than other groups.
Conclusions
The primary endpoint was met; RAM plus DOC after combined chemoimmunotherapy is an effective and relatively feasible second-line treatment in patients with advanced NSCLC in the real-world setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Yamada, K. Takayama: Financial Interests, Personal, Invited Speaker: Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
5P - Clinicopathologic features and genomic profiling of occult breast cancer
Presenter: Liansha Tang
Session: Poster Display
Resources:
Abstract
6P - Tumor cell-released autophagosomes (TRAPs) promote lung metastasis through inducing PD-L1 high expression of pulmonary vascular endothelial cells (PVECs) in breast cancer
Presenter: Xuru Wang
Session: Poster Display
Resources:
Abstract
7P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: Xiaohe Zhou
Session: Poster Display
Resources:
Abstract
9P - Clinicopathological features and prognosis of mucinous breast cancer: A retrospective analysis of 358 patients in Vietnam
Presenter: Hoai Hoang
Session: Poster Display
Resources:
Abstract
10P - Comparison of 28-gene and 70-gene panel in risk-prediction of Chinese women with early-stage HR-positive and HER2-negative breast cancer
Presenter: Lei Lei
Session: Poster Display
Resources:
Abstract
11P - Multimodal analysis of methylation and fragmentomic profiles in plasma cell-free DNA for differentiation of benign and malignant breast tumors
Presenter: Hanh Nguyen
Session: Poster Display
Resources:
Abstract
12P - Plasma cell-free mRNA profiles enable early detection of breast cancer
Presenter: Chi Nguyen
Session: Poster Display
Resources:
Abstract
13P - Relationship of distress and quality of life with gut microbiome composition in newly diagnosed breast cancer patients: A prospective, observational study
Presenter: Chi-Chan Lee
Session: Poster Display
Resources:
Abstract
14P - Classification of molecular subtypes of breast cancer in whole-slide histopathological images using a novel deep learning algorithm
Presenter: Hyung Suk Kim
Session: Poster Display
Resources:
Abstract
15P - The regulation of pregnenolone in breast cancer
Presenter: Hyeon-Gu Kang
Session: Poster Display
Resources:
Abstract